CJC-1295 measurably increases growth hormone and IGF-1 levels in the small number of human studies that have tested it. In that narrow, pharmacological sense – doing what it was designed to do – it does indeed work. Whether that hormonal effect translates to broader outcomes people often associate with it, like muscle gain, fat loss, or anti-aging, is a separate question that current research simply doesn’t answer. This distinction matters and shapes every section below.
Does CJC-1295 really work?
Strictly judged by its intended biological action—stimulating growth hormone release—CJC-1295 has direct human evidence confirming it works. However, this relies on a small body of early-stage clinical research, not large-scale studies. The principal human research involved two randomized, placebo-controlled, double-blind trials in healthy adults aged 21–61. Researchers tested both single escalating doses and multiple dosing regimens over 28 and 49 days, finding that CJC-1295 elicited dose-dependent increases in both growth hormone and IGF-1, without any reported serious adverse events [1]. A separate study added a significant detail: this hormone-increasing effect preserved the body's natural pulsatile release pattern, rather than simply flooding the system continuously, while still significantly raising the baseline level of circulating growth hormone between pulses [2].
Additional supporting evidence comes from animal studies. In mice genetically engineered to lack GHRH—a model of growth hormone deficiency—daily injections of CJC-1295 normalized body weight and length compared to untreated animals, demonstrating that the compound has real, measurable biological activity beyond the test tube [3].
Together, these findings support the claim that CJC-1295 is pharmacologically active and indeed increases growth hormone and IGF-1. However, it is worth reiterating that „whether it works” in terms of visible physical results, disease treatment, or performance enhancement is a separate and much less studied question—one where the evidence is considerably more modest.
How much does CJC-1295 increase HGH?
Human data show a clear dose-dependent relationship between CJC-1295 and growth hormone secretion, although the precise magnitude is heavily dependent on dose and measurement method. In a primary human study, a single injection produced mean plasma growth hormone increases ranging from two- to tenfold above baseline, lasting for six days or longer, with the magnitude of the increase scaling upward with higher doses [1]. IGF-1—generally considered a more stable, long-term marker of growth hormone activity than growth hormone itself due to growth hormone being released in short pulses while IGF-1 gradually builds up—increased 1.5- to threefold and remained elevated for nine to eleven days after a single dose [1].
When CJC-1295 was administered repeatedly over many weeks, IGF-1 levels remained above baseline for up to 28 days. Researchers also noted evidence of a cumulative effect, meaning that repeated dosing built upon itself rather than simply repeating the same isolated spike each time [1].
A control study specifically analyzing the hormone release pattern added an interesting detail. Even during this sustained stimulation, growth hormone was still released in the body's normal pulsatile bursts, rather than as a flat, continuous elevation. The frequency and size of the individual pulses remained roughly the same, but the „trough” level—the low point between pulses—increased dramatically, by about 7.5 times. This trough increase was identified as the main driver of the overall rise in mean growth hormone and the resulting increase in IGF-1 [2].
It is worth noting that the specific numbers above—the multiple increases and the number of days—come from one set of studies in one specific population of healthy adults, using specific dose levels, most significantly around 30–90 micrograms per kilogram. These numbers should not be assumed to generalize precisely to every dose, population, or administration schedule.
Benefits of CJC-1295 for women
There are no published human studies that specifically analyzed CJC-1295 in women or measured outcomes unique to female physiology. For this reason, it is not possible to make evidence-based statements about dosing, outcomes, or anti-aging effects specifically for women. The main pharmacokinetic and hormonal studies of CJC-1295 recruited adults generally described as healthy volunteers, without reporting sex-specific analyses or separate outcome data by sex [1], [2]. This gap is noteworthy because growth hormone physiology can differ significantly between men and women.
For context, a separate study concerning another growth hormone secretagogue, ipamorelin, specifically examined usage patterns by women based on data from online forums. It found that women using such compounds reported concerns regarding sex-specific effects on dosing and long-term consequences, and researchers called for public health attention to this understudied area [4]. This study, however, was a netnography—an analysis of online forum discussions—rather than a clinical or biological study, and it concerned a different peptide, not CJC-1295 directly.
Given the complete lack of dedicated clinical data on CJC-1295 in women, any claims of female-specific benefits, dosing protocols, or anti-aging outcomes should be considered unsupported by current evidence rather than confirmed.
What happens after stopping CJC-1295?
No study identified in the peer-reviewed literature has directly measured what happens after humans cease CJC-1295. Questions about „withdrawal effects” or cessation outcomes, therefore, cannot currently be answered with direct evidence. What can be reasonably inferred comes from the known pharmacokinetics of the compound. Since CJC-1295, in its long-acting, albumin-bound form, has an estimated half-life of about 5.8–8.1 days, its hormone-stimulating effects would be expected to gradually taper off over one to several weeks following the last dose, rather than halt abruptly—as it takes time for the body to clear a compound with such a long half-life [1]. This is, however, a pharmacokinetic inference based on how the compound is cleared from the body, not a finding from a study that actually followed humans post-cessation. It should not be treated as confirmed.
Regarding the related question of using CJC-1295 „alone” versus in combination with a compound like ipamorelin, something is worth clarifying. Human studies that generated the main evidence for CJC-1295's effects on growth hormone and IGF-1 tested it as a standalone compound, meaning the hormonal data for standalone use previously described in this article actually reflect CJC-1295 used on its own [1], [2]. Any additional effect that might arise from combining it with another peptide has significantly more modest support, relying primarily on animal data and mechanistic reasoning rather than direct comparative human research.
Limitations of current evidence
The clearest and most credible evidence for CJC-1295 pertains to its hormonal activity—that it actually increases growth hormone and IGF-1 in a dose-dependent, pulsatile manner in healthy adults.
Everything outside of this main finding involves significantly more uncertainty. There are no dedicated studies in women. There is no controlled data on what happens after stopping the compound. And the evidence base in humans generally relies on a small number of early-stage studies rather than large, diverse, or long-term clinical trials. Readers should be wary of sources that extend well-supported hormonal findings to broader claims about sex-specific benefits or withdrawal effects, as these extensions are not yet supported by direct research.
Disclaimer
This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. CJC-1295 is a research compound and is not approved by the FDA or the European Medicines Agency for any medical use. Human evidence is limited to a small number of early-stage studies measuring hormone levels in healthy adults, and there are no dedicated studies analyzing its use in women, effects upon discontinuation, or long-term safety. Further research is needed before conclusive statements can be made.
References
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
[3] Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290–E1294. https://doi.org/10.1152/ajpendo.00201.2006
[4] Van Hout, M. C., & Hearne, E. (2016). Netnography of female use of the synthetic growth hormone CJC-1295: Pulses and potions. Substance Use & Misuse, 51(1), 73–84. https://doi.org/10.3109/10826084.2015.1082595